Riskpilot← Back to searchSign inGet full accessBAGN APOTEK AS
ASActiveOrg 992316314Retail sale of pharmaceutical products · NACE 4773Est. 20087 employees
Revenue 2025
NOK 17,6M
+4% vs 2024
EBITDA margin
5.0%
+5% vs 2024
Equity ratio
31.3%
Financial strength
Net profit 2025
NOK 735K
+1% vs 2024
| Revenue | NOK 17,6M | +4% |
| EBITDA | NOK 874K | +5% |
| Net profit | NOK 735K | +1% |
| Total assets | NOK 4,8M | +5% |
| Equity | NOK 1,5M | +2% |
| Employees | 7 | — |
Legal name
BAGN APOTEK AS
Org number
992316314
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
14. februar 2008
Share capital
NOK 100 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder i fellesskap.
Company purpose
Selv eller gjennom hel- eller deleide selskaper eller ved samarbeide med andre virksomheter å drive apotekervirksomhet og annen virksomhet beslektet med dette.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 16 464 | 16 903 | 16 458 | 16 994 | 17 595 |
| Staff expenses | −2 819 | −2 906 | −3 085 | −3 296 | −3 270 |
| EBITDA | 1 216 | 1 050 | 847 | 835 | 874 |
| Depreciation & amort. | −0 | −4 | −5 | −9 | −20 |
| EBIT | 1 216 | 1 046 | 842 | 826 | 854 |
| Net financials | 17 | 22 | 66 | 101 | 90 |
| Profit before tax | 1 232 | 1 068 | 908 | 927 | 944 |
| Tax | 269 | 233 | 198 | 202 | 209 |
| Net profit | 964 | 835 | 710 | 725 | 735 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 858 | 4 554 | 5 982 | 4 603 | 4 843 |
| Equity | 1 212 | 1 447 | 1 457 | 1 482 | 1 517 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 646 | 3 107 | 4 525 | 3 121 | 3 326 |
| Total debt | 3 646 | 3 107 | 4 525 | 3 121 | 3 326 |
EBITDA margin
5.0%
This company
15.8%
Market median
-68% vs market
20212025
Equity ratio
31.3%
This company
38.2%
Market median
+18% vs market
20212025
Return on equity
48.4%
This company
18.4%
Market median
+163% vs market
20212025
Net profit margin
4.2%
This company
8.1%
Market median
-48% vs market
20212025
Asset turnover
3.63×
This company
1.12×
Market median
+224% vs market
20212025
Debt / equity
2.19×
This company
0.62×
Market median
-253% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SB Chief Executive Officer | Chief Executive Officer | 2008 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2008 | |
| Board of Directors | 2008 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BAGN APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sidsel Bjone | Chief Executive Officer | 0 companies |
| Kari-Anne Rustebakke | Chairman | 0 companies |
| Kai Reidar Dølven | Board of Directors | 0 companies |